Fluorescence resonance energy transfer usage to track the sequence promoter changes in CGB5 gene in ovarian cancer patients - 04/05/17
, Izabela Skibińska a , Emilia Gąsiorowska b , Piotr Białas a , Małgorzata Kotwicka a Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Purpose |
The survival rates for ovarian cancer patients remain very low, often as a result of late diagnosis due to the asymptomatic course of the early stage disease. Based on the important biological contribution of human chorionic gonadotropin to various key processes including; cell cycle control, DNA repair, cellular differentiation and developmental processes, we hypothesized that genetic polymorphisms in the genes promoter could be associated with ovarian cancer risk. Thus, the purpose of the study was to determine whether particular polymorphisms occur in the promoter region of the human chorionic gonadotropin polypeptide 5 encoding gene, and if so, are they associated with ovarian cancer outcome.
Patients and methods |
We analyzed Central European females diagnosed with ovarian cancer (n=95) and controls (n=76) for the occurrence of at least one of three polymorphisms (rs7260002, rs7246045, rs540432391) and their impact on cancer risk. The fluorescence resonance energy transfer technique was used in order to conduct single nucleotide polymorphisms genotyping.
Results |
The occurrence of two studied polymorphisms, rs7260002 and rs540432391 present in the 5′ upstream region of the chorionic gonadotropin (CG) gene were associated with an increased risk of ovarian cancer. The former polymorphism had a minor impact on cancer risk (P=0.049; OR=1.95; 95% CI=0.97–3.92), while the latter had a much larger impact and may be of great importance in the evaluation of cancer development in the analyzed population (p<0.001; OR 8.5; 95% CI 3.59–20.23).
Conclusions |
The fluorescence resonance energy transfer application used in tracking the sequence promoter variations of genes expressed during tumorigenesis may be an important factor in early prediction of ovarian cancer. Taking under consideration the elevated CG expression associated with several different cancer types it seems reasonable to estimate if the analyzed polymorphisms could affect cancer outcome.
Le texte complet de cet article est disponible en PDF.Abbreviations : FRET, CG, CGB, CGB5/8, SNP, TSS
Keywords : DNA sequence changes, FRET – fluorescence resonance energy transfer, Genotype, Human chorionic gonadotropin, Ovarian cancer, Single nucleotide polymorphism
Plan
Vol 90
P. 139-146 - juin 2017 Retour au numéro
Article précédent
- Induction of apoptotic DNA fragmentation mediated by mitochondrial pathway with caspase-3-dependent BID cleavage in human gastric cancer cells by a new nitroxyl spin-labeled derivative of podophyllotoxin
- Yu-Jie Yang, She-Ning Qi, Rui-Yue Shi, Jun Yao, Li-Sheng Wang, Hu-Qin Yuan, Yuan-Xue Jing
- Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4)
- Youguang Zhao, Zhitao Wei, Hang Yang, Xiaowei Li, Qiwu Wang, Liang Wang, Shadan Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?